Welireg

Generic name: belzutifan

Used for: Tumors from von Hippel-Lindau (VHL) disease · Kidney cancer with a clear cell component (ccRCC) · Pheochromocytoma or paraganglioma (PPGL) · 2 more

How do you pay?

How to pay the least

Ask for the cash price

Welireg

We didn’t find one.

  1. Ask your pharmacy for Welireg’s cash price, and one or two other pharmacies too.
  2. Welireg’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Merck Patient Assistance Program. You may qualify for the program if you have a household income of $63,840 or less for individuals, $86,560 or less for couples, or $132,000 or less for a family of 4. Or call 800-727-5400.

See if you qualify 

Compare every option

Question
Brand nameWelireg
Authorized genericbelzutifan
Regular genericbelzutifan
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Welireg?
The original
–
–

Brand nameThe maker’s card

WELIREG Savings Coupon

Savings card from Merck

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $5 a prescription

The card takes up to $10,150 per patient off your co-pay.

Sign up on activatethecard.com 

In the maker’s words

“Eligible, privately insured patients may pay as little as $5 per prescription on each qualifying prescription.”

From the maker’s offer on activatethecard.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Welireg itself, from the same company, sold without the brand name, and usually for less. For now Welireg is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

WELIREG is a hypoxia-inducible factor inhibitor indicated:

von Hippel-Lindau disease

  • for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Renal Cell Carcinoma with a Clear Cell Component

  • in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the adjuvant treatment of adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
  • in combination with lenvatinib for the treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
  • as monotherapy, for treatment of adult patients with advanced ccRCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Pheochromocytoma or Paraganglioma

  • for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

Source: the FDA label for Welireg (Merck Sharp & Dohme LLC), September 24, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/welireg/